Pfizer Oral S1P Modulator for Ulcerative Colitis Meets Primary Endpoint of Phase 3 Trials
- EB Virus Could Be Infected by Kiss: A Hidden Threat Linked to Cancer
- The Silent Threat: How Gas Stoves Pollute Our Homes and Impact Health
- Paternal Microbiome Perturbations Impact Offspring Fitness
- New Report Casts Doubt on Maradona’s Cause of Death and Rocks Manslaughter Case
- Chinese academician unable to provide the exact source of liver transplants
- Early Biomarker for Multiple Sclerosis Development Identified Years in Advance
Pfizer Oral S1P Modulator for Ulcerative Colitis Meets Primary Endpoint of Phase 3 Trials
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Pfizer Oral S1P Modulator for Ulcerative Colitis Meets Primary Endpoint of Phase 3 Trials
On March 23, 2022, Pfizer announced positive top-line results from a Phase 3 clinical trials of Etrasimod (ADP334).
Etrasimod is an investigational once-daily oral selective sphingosine 1-phosphate (S1P) receptor modulator being developed for the treatment of moderately to severely active ulcerative colitis (UC).
The trial met its primary endpoint of a statistically significant improvement in clinical remission at week 12 in the Etrasimod group compared to placebo. And, the trial showed significant improvement on all key secondary endpoints.
UC is a chronic, often debilitating inflammatory bowel disease. Symptoms of the disease can include chronic diarrhea with blood and mucus, abdominal pain and cramping, and weight loss, and have a significant impact on the patient’s work, family, and social activities.
At present, the treatment of this disease mainly lies in the inhibition of intestinal inflammation.
However, the existing treatment methods, such as aminosalicylic acid, glucocorticoids, immunosuppressants or biological agents, are not satisfactory in terms of safety and efficacy.
With the deepening of basic research on the immune system, therapeutic targets related to the mechanism of inflammation have been continuously discovered, and a variety of new targeted drugs have been used in treatment. Among them, S1P receptor modulators are the current research and development hotspot.
Etrasimod was developed by Arena Pharmaceuticals, which was acquired by Pfizer in December.
Etrasimod is a next-generation oral S1P modulator that specifically binds to S1P receptors 1, 4, and 5 and may have a better efficacy/safety profile.
The investigational therapy is currently being investigated for a range of immune-inflammatory diseases, including UC, Crohn’s disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata.
Image source: Pfizer’s official website
This multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial enrolled 354 patients with UC who had previously failed or were intolerant to at least one conventional therapy/biologic/JAK therapy.
References:
[1] Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients. Retrieved March 23, 2022, from https://www.businesswire.com/news/home/20220323005370/en/Pfizer-Announces-Positive-Top-Line-Results-for-Phase-3-Trial-of-Etrasimod-in-Ulcerative-Colitis-Patients
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.